• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

醛糖还原酶抑制剂的药代动力学种间比较。

Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.

作者信息

Brazzell R K, Park Y H, Wooldridge C B, McCue B, Barker R, Couch R, York B

机构信息

Alcon Laboratories, Inc., Fort Worth, TX 76134.

出版信息

Drug Metab Dispos. 1990 Jul-Aug;18(4):435-40.

PMID:1976064
Abstract

The pharmacokinetics of three aldose reductase inhibitors (ARIs) were evaluated in various species, including rat, dog, cynomolgus monkey, rhesus monkey, chimpanzee, and man. The three ARIs (AL01567, AL01576, and AL01750) were administered intravenously as a single dose to all species except rat, which was dosed orally with AL01750, and man, who was dosed orally with AL01567 and AL01576. Plasma drug concentrations were measured by HPLC or liquid scintillation spectrometry and various pharmacokinetic parameters (clearance, CL; Vd, volume of distribution; and t1/2) were calculated from the data. Overall the pharmacokinetics of the three compounds were quite similar, each being characterized by low CL, intermediate Vd, and long t1/2. For AL01576, mean CL ranged from 0.21 ml/min/kg in cynomolgus monkey to 0.91 ml/min/kg in dog, mean Vd from 0.66 liter/kg in cynomolgus monkey to 2.4 liters/kg in dog and man and mean t1/2 from 29 hr in dog to 72 hr in man. Mean CL of AL01567 ranged from 0.14 ml/min/kg in man to 1.4 ml/min/kg in dog, mean Vd from 0.45 liter/kg in rat to 3.5 liters/kg in dog and mean t1/2 from 22 hr in rhesus monkey to 63 hr in man. Mean CL of AL01750 ranged from 0.13 ml/min/kg in chimpanzee to 1.3 ml/min/kg in dog, mean Vd from 0.40 liter/kg in rat to 1.8 liters/kg in dog and mean t1/2 from 12 hr in rhesus monkey to 62 hr in chimpanzee. For all three drugs, CL and Vd corrected for body weight were quite similar in all species except dog, whose CL and Vd were two- to fourfold greater than the other animals.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在包括大鼠、狗、食蟹猴、恒河猴、黑猩猩和人类在内的多种物种中评估了三种醛糖还原酶抑制剂(ARI)的药代动力学。除大鼠经口给予AL01750以及人类经口给予AL01567和AL01576外,三种ARI(AL01567、AL01576和AL01750)均以单剂量静脉注射给予所有物种。通过高效液相色谱法或液体闪烁光谱法测量血浆药物浓度,并根据数据计算各种药代动力学参数(清除率,CL;分布容积,Vd;以及半衰期,t1/2)。总体而言,这三种化合物的药代动力学非常相似,其特征均为低CL、中等Vd和长t1/2。对于AL01576,平均CL范围从食蟹猴的0.21毫升/分钟/千克到狗的0.91毫升/分钟/千克,平均Vd从食蟹猴的0.66升/千克到狗和人类的2.4升/千克,平均t1/2从狗的29小时到人类的72小时。AL01567的平均CL范围从人类的0.14毫升/分钟/千克到狗的1.4毫升/分钟/千克,平均Vd从大鼠的0.45升/千克到狗的3.5升/千克,平均t1/2从恒河猴的22小时到人类的63小时。AL01750的平均CL范围从黑猩猩的0.13毫升/分钟/千克到狗的1.3毫升/分钟/千克,平均Vd从大鼠的0.40升/千克到狗的1.8升/千克,平均t1/2从恒河猴的12小时到黑猩猩的62小时。对于所有三种药物,除狗外,所有物种中经体重校正的CL和Vd非常相似,狗的CL和Vd比其他动物大两到四倍。(摘要截断于250字)

相似文献

1
Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.醛糖还原酶抑制剂的药代动力学种间比较。
Drug Metab Dispos. 1990 Jul-Aug;18(4):435-40.
2
Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.通过生物测定法测定大鼠晶状体和血浆中AL01576的浓度以进行醛糖还原酶活性测量。
Ophthalmic Res. 1989;21(4):285-91. doi: 10.1159/000266871.
3
The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
J Ocul Pharmacol. 1989 Fall;5(3):233-40. doi: 10.1089/jop.1989.5.233.
4
High-performance liquid chromatographic assay of the aldose reductase inhibitor spiro-(2-fluoro-9H-fluorene-9,4'-imidazolidine)-2',5'-dione (AL01567) in plasma and urine and its pharmacokinetics in humans.血浆和尿液中醛糖还原酶抑制剂螺-(2-氟-9H-芴-9,4'-咪唑烷)-2',5'-二酮(AL01567)的高效液相色谱测定及其在人体中的药代动力学
J Pharm Sci. 1988 Jul;77(7):591-5. doi: 10.1002/jps.2600770709.
5
Disposition of the aldose reductase inhibitor AL01576 in rats.醛糖还原酶抑制剂AL01576在大鼠体内的处置情况。
J Pharm Sci. 1988 Feb;77(2):110-5. doi: 10.1002/jps.2600770204.
6
Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.绿草定(3,5,6-三氯-2-吡啶氧基乙酸)在比格犬和恒河猴体内的药代动力学:关于犬相对于大鼠、猴和人类排泄这种有机酸能力降低的研究视角
Toxicol Appl Pharmacol. 1997 Jun;144(2):268-78. doi: 10.1006/taap.1997.8136.
7
Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).醛糖还原酶抑制剂AL03152(RS)、AL03802(R)和AL03803(S)的药代动力学和药效学比较。
Pharm Res. 1993 Apr;10(4):593-7. doi: 10.1023/a:1018962405911.
8
[Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts].醛糖还原酶抑制剂M79175对实验性糖性白内障的影响
Nippon Ganka Gakkai Zasshi. 1982;86(9):1343-50.
9
Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.结构相关的螺乙内酰脲和螺琥珀酰亚胺醛糖还原酶抑制剂的药代动力学及疗效
Xenobiotica. 1992 May;22(5):543-50. doi: 10.3109/00498259209053117.
10
Interspecies comparison of acivicin pharmacokinetics.
Drug Metab Dispos. 1988 Jan-Feb;16(1):18-22.

引用本文的文献

1
Allometric scaling of xenobiotic clearance: uncertainty versus universality.异生物清除的异速生长缩放:不确定性与普遍性
AAPS PharmSci. 2001;3(4):E29. doi: 10.1208/ps030429.
2
SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.
Pharm Res. 2001 Sep;18(9):1336-44. doi: 10.1023/a:1013002414678.
3
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).肠胃外抗真菌药物MK-0991(L-743,872)的初步动物药代动力学研究
Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44. doi: 10.1128/AAC.41.11.2339.
4
Scaling basic toxicokinetic parameters from rat to man.将大鼠的基本毒代动力学参数外推至人体。
Environ Health Perspect. 1996 Apr;104(4):400-7. doi: 10.1289/ehp.96104400.
5
Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).醛糖还原酶抑制剂AL03152(RS)、AL03802(R)和AL03803(S)的药代动力学和药效学比较。
Pharm Res. 1993 Apr;10(4):593-7. doi: 10.1023/a:1018962405911.
6
Metabolism of the aldose reductase inhibitor ALO1567 in man.醛糖还原酶抑制剂ALO1567在人体中的代谢。
Br J Clin Pharmacol. 1991 Aug;32(2):221-7. doi: 10.1111/j.1365-2125.1991.tb03885.x.
7
Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.醛糖还原酶抑制剂依米司他在人体中的剂量依赖性药代动力学。
Pharm Res. 1991 Jan;8(1):112-8. doi: 10.1023/a:1015850911382.
8
Saturable tissue binding and imirestat pharmacokinetics in rats.大鼠体内的饱和组织结合与依米司他的药代动力学
Pharm Res. 1992 Apr;9(4):469-73. doi: 10.1023/a:1015880011131.